medigraphic.com
SPANISH

Mediciego

ISSN 1029-3035 (Electronic)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2019, Number 3

<< Back Next >>

Mediciego 2019; 25 (3)

Effectiveness of oleozon in the treatment of recurrent aphthous stomatitis

Leal-Rodríguez MI, Leyva-Céspedes N, Zamora-Guevara N
Full text How to cite this article

Language: Spanish
References: 7
Page: 297-304
PDF size: 357.80 Kb.


Key words:

aphthous stomatitis/therapy, ozone/therapeutic use, treatment outcome, phase IV clinical trial, randomized controlled trials as topic.

ABSTRACT

Introduction: recurrent aphthous stomatitis is one of the most frequent and painful alterations of the oral complex.
Objective: to evaluate the effectiveness of oleozon in the treatment of recurrent aphthous stomatitis.
Method: a randomized controlled phase IV clinical trial was carried out on 120 patients aged 15 to 35 years, with a clinical diagnosis of recurrent aphthous stomatitis who attended the emergency department of the Mayarí Stomatological Clinic, Holguín province, between April 2017 and February 2018. Oleozon was applied to the study group, and the conventional drug treatment was applied to the control group. The bioethical principles defined for this type of study were fulfilled.
Results: stomatitis predominated in the study group at the ages of 25 to 35 years (63,33 %) and in the female sex (75,00 %). It was observed that the majority of patients treated with ozonized oil (93,33 %) healed on the seventh day. However, in the control group only 56,67 % healed.
Conclusions: oleozon is effective in the aphthae healing, with a shorter therapeutic response time than conventional treatment.


REFERENCES

  1. Troya-Borges E, Martínez-Abreu J, Padilla-Suárez E, Iglesias-López N, Ramos-Ortega A. La estomatitis aftosa recurrente y las situaciones de estrés como factor de riesgo. Rev Méd Electrón [Internet]. Dic 2014 [citado 6 Feb 2018];36(6):799-812. Disponible en: http://scielo.sld.cu/pdf/rme/v36n6/rme010614.pdf

  2. Mederos-García LA, Espasandín-González S, Acosta-Acosta N, Reyes-Suárez VO. Tratamiento de la estomatitis aftosa recurrente con laserterapia. Medimay [Internet]. 2014 [citado 6 Feb 2018];20(3):401-13. Disponible en: http://revcmhabana.sld.cu/index.php/rcmh/article/view/665/pdf_12

  3. Báez-Matos CL, Frías-Banqueros M, Ayala-Báez SC. Ozonoterapia en un paciente portador de aftas bucales. A propósito de un caso. Multimed [Internet]. 2015 [citado 6 Feb 2018];19(3):178-87. Disponible en: http://www.revmultimed.sld.cu/index.php/mtm/article/view/360/565

  4. Fontaine-Machado O, Fontaine-Uliver MC, Pérez-Alfonzo DO, Núñez-Oduardo EA, García-Jiménez AM. El oleozón en el tratamiento de la estomatitis aftosa. Rev. Hallazgos21 [Internet]. 2016 [citado 20 Mar 2018];1(2):125-35. Disponible en: http://revistas.pucese.edu.ec/hallazgos21/article/view/22/31

  5. Martínez-Abreu J, Guerra-Fontén N, Blanco-García A, Naranjo-Rodríguez S, Llanes-Llanes E, Menéndez-Cepero S. Efficacy of OLEOZON® compared to Alvogil in the treatment of alveolitis. Journal of Ozone Therapy [Internet]. 2015. [citado 23 Mar 2018];1(1):[aprox. 8p.]. Disponible en: https://ojs.uv.es/index.php/JO3T/article/download/12162/pdf

  6. Casado-Tamayo D, Quezada-Oliva LM, Casado-Méndez PR, Santos-Fonseca RS, Méndez-Jiménez O, Pérez-Villavicencio AM. Efectividad del tratamiento con oleozón versus crema de aloe en la estomatitis subprotésica. AMC [Internet]. Abr 2017 [citado 23 Mar 2018];21(2):202-12. Disponible en: http://scielo.sld.cu/pdf/amc/v21n2/amc050217.pdf

  7. Castelnaux-Martínez M, Jiménez-Fuentes A, Navarro-Nápoles J, González-Sánchez Y, Rodríguez- Sierras Z. Estomatitis aftosa recurrente según factores locales y generales. MEDISAN [Internet]. Sep 2013 [citado 16 Abr 2018];17(9):5027-34. Disponible en: http://scielo.sld.cu/pdf/san/v17n9/san10179.pdf




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Mediciego. 2019;25